The effects of intravitreal ophthalmic medications on intraocular pressure

Seminars in Ophthalmology

Volumn 24, Issue 2, 2009, Pages 100-105

  Wu, Huijuan ^a   Chen, Teresa C ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Antibiotics Macugen; Antiviral Agents; Avastin; Bevacizumab; Injections; Intraocular pressure; Lucentis; Pegaptanib; Ranibizumab; Triamcinolone acetonide; Vitreous body

Indexed keywords

BEVACIZUMAB; CIDOFOVIR; CORTICOSTEROID; GANCICLOVIR; PEGAPTANIB; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; EYE DROPS; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

CATARACT EXTRACTION; CLINICAL TRIAL; DRUG EFFECT; GLAUCOMA; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; PROPHYLAXIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SECONDARY GLAUCOMA; SIDE EFFECT; DRUG ANTAGONISM; INJECTION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 66149134082     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530902800397     Document Type: Review

References (68)

1. Von Sallmann L, Meyer K , Di Grandi J. Experimental study of penilillin treatment of ectogenous infection of vitreous. Arch Ophthalmol. 1944;32:179
2. Duguid JP, Ginsberg M, Fraser IC, et al. Experimental observations on the intraviteous use of penicillin and other drugs. Br J Ophthalmol. 1947 Apr;31(4):193-211.
3. Daily MJ, Peyman GA, Fishman G. Intravitreal injection of methicillin for treatment of endophthalmitis. Am J Ophthalmol. 1973 Sep;76(3):343-350.
4. Peyman GA, Vastine DW, Meisels HI. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol. 1975 Nov 21;39(1):183- 201.
5. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987 Jan 15;103(1):17-23.
6. Luu KK, Scott IU, Chaudhry NA, et al. Intravitreal antiviral injections as adjunctive therapy in the management of immuno-competent patients with necrotizing herpetic retinopathy. Am J Ophthalmol. 2000 Jun;129(6):811-813.
7. Blankenship GW. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch Clin Exp Ophthalmol. 1991;229(1):62-65.
8. PenfoldPL,GyoryJF, Hunyor AB, BillsonFA.Exudativemacu-lar degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol. 1995 Nov;23(4):293-298.
9. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results. Arch Ophthalmol. 2003 May;121(5):667-673.
10. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol. 2003 Aug;136(2):384-386.
11. Gómez-Ulla F, Marticorena J, Alfaro DV 3rd, et al. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev. 2006 Feb;2(1):99-112.
12. Alldredge CD, Garretson BR: Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-6.
13. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005 Nov;112(11):1916.e1-e7.
14. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131: 468-471.
15. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27): 2805-2816.
16. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol. 2008 Aug;92(8):1035-1039.
17. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006 Nov-Dec;26(9):999-1005.
18. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007 Feb;27(2):141-149.
19. Han DP. Endophthalmitis. In Alber DM, ed. Ophthalmic Surgery: Principles and Techniques. Malden: Blackwell Science, 1999;650-662.
20. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-133.
21. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2004, 26:859-870
22. Tsamparlakis JC. Effects of transient induced elevation of the intraocular pressure on the visual field. Br J Ophthalmol. 1964 May;48:237-249.
23. Scott AB, Morris A. Visual field changes produced by artificially elevated intraocular pressure. Am J Ophthalmol. 1967 Feb;63(2):308-312.
24. Moster, MR, Moster, ML. Wipe-out: A complication of glaucoma surgery or just a blast from the past? Am J Ophthalmol. 2005 Oct;140(4):705-706.
25. Lanzl IM, Moster MR, Hodges DD. Intraoperative prediction of intraocular pressure for the first postoperative day following glaucoma filtration surgery. Ophthalmic Surg Lasers. 1997 Sep;28(9):780-782.
26. Moster MR et al. Invest Ophthalmol Vis Sci 1987;28 (suppl):273.
27. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27:1044 -1047.
28. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008 Dec;146(6):930-934.
29. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006;141:200-201.
30. Lee EW, Hariprasad SM, Mieler WF, et al. Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol 2007;143:365-367.
31. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178.
32. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamci-nolone, pegaptanib, and bevacizumab. Eye. In press.
33. Mojica G, Hariprasad SM, Jager RD, Mieler WF. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008 Apr;92(4): 584.
34. Morlet N, Young SH. Prevention of intraocular pressure rise following intravitreal injection. Br J Ophthalmol. 1993 Sep;77(9): 572-573.
35. Hollands H, Wong J, Bruemn R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
36. Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007 Jun;143(6):1034-1035.
37. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: Clinical results and biomechanical model. Acta Ophthalmol Scand. 2007 Nov;85(7):777-781.
38. Pallikaris IG, Kymionis GD, Ginis HS, et al. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):409-414.
39. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242(2):184-185.
40. Lau LI, Chen KC, Lee FL, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol. 2008 Oct;146(4):573-578.
41. Im L, Allingham RR, Singh I, et al. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection. J Glaucoma. 2008 Mar;17(2): 128-132.
42. Inatani M, Iwao K, Kawaji T, et al. Intraocular pressure elevation after injection of triamcinolone acetonide: A multicenter retrospective case-control study. Am J Ophthalmol. 2008 Apr;145(4):676-681.
43. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006 Aug; 90(8):999-1003.
44. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593- 598.
45. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after in-travitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003; Jan 87(1):24-27.
46. Jonas JB, Degenring R, Kreissig I, et al. Safety of intravitreal high-dose reinjections of treiamcinoloneacetonide. Am J Ophthalmol. 2004 Dec;138(6):1054-1055.
47. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004 Nov;138(5):740-743.
48. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004;122(3):336-340.
49. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005 Jun;19(2):122-127.
50. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors. Retina 2008;28:573-580.
51. Shields MB: Steroid-induced glaucoma. In Shields MB, ed. Textbook of Glaucoma, 3rd edition, Baltimore: Williams & Wilkins, 1992;374-380.
52. Kubota T, Okabe H, Hisatomi T, et al. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006;15(2):117- 119.
53. Shinzato M, Yamashiro Y, Miyara N, et al. Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: Downregulation of type I collagen C-propeptides. Ophthalmic Res 2007;39(6):330-337.
54. Rozsa FW, Reed DM, Scott KM, et al. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis 2006;12:125-141.
55. Bill A. The drainage of aqueous humor. Invest Ophthal. 1975;14: 1.
56. Singh IP, Ahmad SI, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004 Aug;138(2):286-287.
57. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-1444.
58. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-1431.
59. Wu L, Mart́inez-Castellanos MA, Quiroz-Mercado H, et al., for the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-87.
60. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-958. In press.
61. Jalil A, Fenerty C, Charles S. Intravitreale bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye. 2007 Dec;21(12):1541. In press.
62. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal Bevacizumab injections. Ophthalmic Surg Lasers Imaging. In press.
63. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008 Oct; 146(4):508-512. In press.
64. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495- 511.
65. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-345. In press.
66. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999 Sep-Oct;27(5):536-544.
67. Banker AS, Arevalo JF, Munguia D, et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol. 1997 Aug;124(2):168-180.
68. Taskintuna I, Banker AS, Rao NA, et al. An animal model for cidofovir (HPMPC) toxicity: Intraocular pressure and histopathologic effects. Exp Eye Res. 1997 May;64(5):795-806.